Buprenorphine/naloxone - Orexo

Drug Profile

Buprenorphine/naloxone - Orexo

Alternative Names: Naloxone/buprenorphine - Orexo; OX-219; PKX-219; Zubsolv

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator PharmaKodex
  • Developer Orexo
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Opioid abuse

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 01 Mar 2017 Orexo initiates litigation against Actavis over generic versions of Suboxone® and Subutex in USA
  • 16 Nov 2016 Orexo receives patent allowance for buprenorphine/naloxone in USA
  • 06 Oct 2016 Orexo plans to launch 0.7mg/0.18mg buprenorphine/naloxone for Opioid abuse in early 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top